TRPM6

Across TCGA pan-cancer cohorts, TRPM6 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated TRPM6 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TRPM6 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated TRPM6 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

STAD, UCEC, and CESC are the cancer types where TRPM6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	III,IV	1.000	0.326	.009	24	view →
UCEC	DFS	Median	All	0.778	0.625	.017	20	view →
CESC	DFS	Median	IV	0.053	0.529	<.001	14	view →
SKCM	DFS	Median	II,III,IV	0.894	0.634	.001	13	view →
LUSC	OS	Median	All	0.310	0.736	.002	8	view →
KIRC	DFS	Median	All	0.127	0.865	<.001	6	view →
DLBC	OS	Median	All	0.053	0.936	<.001	6	view →
LUAD	OS	Median	III,IV	0.057	0.680	<.001	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SCLC	DFS	Median	III,IV	0.252	0.567	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

TRPM6–STAD (DFS)

Open the STAD breakdown →